Reversing multidrug resistance by tyrosine kinase inhibitors

作     者：Miao He Min-Jie Wei 

作者机构：Department of PharmacologyPharmaceutical Collegeof China Medical UniversityShenyangLiaoning 110001P.R.China. 

出 版 物：《Chinese Journal of Cancer》 (Chinese Journal of Cancer)

年 卷 期：2012年第31卷第3期

页      面：126-133页

核心收录：

学科分类：0710[理学-生物学] 1007[医学-药学(可授医学、理学学位)] 071010[理学-生物化学与分子生物学] 081704[工学-应用化学] 07[理学] 08[工学] 0817[工学-化学工程与技术] 10[医学] 

基　　金：supported by grantsfrom the National Natural Science Foundation of China(No. 30873097) Research Fund for the Doctoral Program of Higher Education of China (No.20092104110020) Science and Technology Planning Project of Liaoning Province,China (No.2010225001) 

主　　题：酪氨酸激酶抑制剂 多药耐药 逆转 转运蛋白 肿瘤细胞 ABC 抗癌药物 信号通路 

摘      要：Recently,a large number of tyrosine kinase inhibitors(TKIs) have been developed as anticancer *** TKIs can specifically and selectively inhibit tumor cell growth and metastasis by targeting various tyrosine kinases and thereby interfering with cellular signaling *** therapeutic potential of TKIs has been hindered by multidrug resistance(MDR),which is commonly caused by overexpression of ATP-binding cassette(ABC) membrane ***,some TKIs have also been found to reverse MDR by directly inhibiting the function of ABC transporters and enhancing the efficacy of conventional chemotherapeutic *** this review,we discuss ABC transporter-mediated MDR to TKIs and MDR reversal by TKIs.